These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26283274)

  • 1. Epilogue: The future of Laron syndrome - The need for changes.
    Laron Z
    Growth Horm IGF Res; 2016 Jun; 28():79-80. PubMed ID: 26283274
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic and therapeutic advances in growth hormone insensitivity.
    David A; Metherell LA; Clark AJ; Camacho-Hübner C; Savage MO
    Endocrinol Metab Clin North Am; 2005 Sep; 34(3):581-95, viii. PubMed ID: 16085161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders.
    Savage MO; Attie KM; David A; Metherell LA; Clark AJ; Camacho-Hübner C
    Nat Clin Pract Endocrinol Metab; 2006 Jul; 2(7):395-407. PubMed ID: 16932322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective.
    Rosenbloom AL
    Growth Horm IGF Res; 2016 Jun; 28():46-50. PubMed ID: 26276451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome.
    Konen O; Silbergeld A; Lilos P; Kornreich L; Laron Z
    J Pediatr Endocrinol Metab; 2009 Mar; 22(3):235-9. PubMed ID: 19492579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Laron type dwarfism].
    Okimura Y
    Nihon Rinsho; 2006 May; Suppl 1():94-7. PubMed ID: 16776102
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
    Kemp SF
    BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Competencies for Effective Pediatric Endocrine Nursing Practice.
    Davies K; Dwyer AA
    J Pediatr Nurs; 2019; 48():127-128. PubMed ID: 31409498
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.
    Erol N; Yıldız M; Güven A; Yıldırım A
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):675-679. PubMed ID: 29750649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial hyperglycemia corrected by IGF-I (Increlex®) in Laron syndrome.
    Latrech H; Simon A; Beltrand J; Souberbielle JC; Belmejdoub G; Polak M
    Horm Res Paediatr; 2012; 78(3):193-200. PubMed ID: 22986916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes mellitus with Laron syndrome: case report.
    Agladıoglu SY; Cetınkaya S; Savas Erdeve S; Onder A; Kendırcı HN; Bas VN; Aycan Z
    J Pediatr Endocrinol Metab; 2013; 26(9-10):955-8. PubMed ID: 23729552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
    Laron Z; Kauli R
    Growth Horm IGF Res; 2016 Jun; 28():53-6. PubMed ID: 26307357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further observations on the effects of long-term treatment with recombinant human insulin-like growth factor 1 in growth hormone insensitivity syndrome.
    El Kholy M; Amr NH; Elsedfy H
    Horm Res Paediatr; 2014; 81(4):258-65. PubMed ID: 24642532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.
    Concolino D; Muzzi G; Sestito S; Vega G; Bonapace G; Strisciuglio P
    Eur J Pediatr; 2010 Feb; 169(2):245-7. PubMed ID: 19517134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statement 5: the first line of treatment for children with idiopathic short stature (ISS) and low serum insulin-like growth factor-I (IGF-I) should be IGF-I.
    Backeljauw P
    Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():853-6. PubMed ID: 18438329
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome.
    Bang P; Woelfle J; Perrot V; Sert C; Polak M
    Eur J Endocrinol; 2021 Feb; 184(2):267-276. PubMed ID: 33434161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laron syndrome.
    Guleria S; Sharma J; Kaushik SL
    J Postgrad Med; 2014; 60(3):322-3. PubMed ID: 25121377
    [No Abstract]   [Full Text] [Related]  

  • 20. IGF-I treatment of patients with Laron syndrome suppresses serum thrombopoietin levels but does not affect serum erythropoietin.
    Orit S; Joanne Y; Meira Z; Hannah T; Zvi L
    Am J Hematol; 2009 Jan; 84(1):64. PubMed ID: 19021123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.